Our Team

Our team brings together a wealth of knowledge and industry experience to genomics empowered healthcare.

Board of Directors

Mark Grosser

CEO, Chairman

Mr Grosser has over 25 years’ experience in the health technology industry working across Engineering, Management and R&D at firms such as Cochlear, Micromedical and the Henry Schein group.

Murry Chatfield

Non-Executive Director

Murray is a Finance Professional, with over 30 years in financial markets, trading, financial structuring and risk management, treasury, compliance, operations and corporate governance.

Mark Walsh

CFO & Secretary

Leads a team of Accountants and is a Fellow of the Australian Institute of Public Accountants.He has a Master of Law degree with 30+ years of financial management experience.

Prof. Steven Boyages

Non-Executive Director

Steven is a recognised leader in health innovation and education. He was previously the Medical Director for eHealth NSW.

Omer Ingber

Co-Founder

Omer brings 20 years’ experience across technology leadership, project management, customer success, operations and senior management.

Sales & Marketing

Nicky Conway

Commercialisation Director

Leads our commercialization team and comes from a background of delivering commercialization, regulatory, reimbursement and launch strategies in the diagnostic and pharmaceutical markets. Nicky led the process for gaining a positive recommendation for Preimplantation Genetic Diagnosis (PGD) through MSAC (Genea 2015) from both a technical (HTA) and stakeholder support perspective.

Glenn Gilchrist

Client Relationship Manager

Glenn, based in Brisbane, has over 20 years’ experience working within the Australian Healthcare sector. Glenn’s industry career spans pharmaceutical sales, with a focus on Oncology, medical devices across companies such as WL Gore, Boston Scientific, Fresenius Kabi, Medtronic and ICU Medical.

Clinical & Advisory Board

Steven Tipper

Chief Strategy Officer

Steven has over 35 years of health experience, with 15 years consulting in health business management and translation of Research into commercial delivery.

Prof. Deon Venter

Chief Medical Advisor

Prof Venter pioneered the use of many leading-edge genomic technologies in diagnostics. He has participated in the creation of a number of global healthcare technology companies and is widely published in the genomic literature.

Reproductive and Women's Health

Dr. Vin Smith

Co-founder and Lead Advisor, Reproductive & Women's Health

Vin, based in Melbourne, has led the vision for 23Strands to enter the Women’s Health market and he is a Women's Health Physician (Obs & Gyn) and has a strong track record mentoring health innovation companies. He is leading 23Strands’ clinical relationships in the reproductive health market.

Dr. Fabrizzio Horta

Scientific advisor, reproductive health

Fab has been crucial to incorporating the 23Strands vision into the field of assisted reproductive technologies (ARTS.) He is an expert on ARTS focused on the development of new technologies to improve reproductive outcomes of couples suffering from infertility worldwide.

Data & Science

Dr. Hua Lin

Chief Data Officer

Dr Lin has been a leader in data science and has been applying these skills to real-world healthcare delivery. She was previously the head of data insights at MedicalDirector, Australia’s leading General Practice EMR software.

Dr. Emanuel Birru

Genomics and Bioinformatics

Emanuel brings to the 23Strands team a deep understanding of Bioinformatics and Pharmacogenomics applications to Whole Genome Sequencing as well as drug design, development and delivery skill using computational methods.

Information Technology

Robert Mitreski

Co-founder and Production Director

Leads 23Strands UX team. Extensive front-end developer working with leading companies including Alphapharm, Caesarstone, Samsung and Abbott Australasia.

Nick Devereaux

Co-founder and Technical Lead

Leads 23Strands technical team across transactional and data insights solutions to deliver systems that integrate with business processes and have scope for ongoing growth